Letter to the Editor. Prediction model of IDH wild-type glioblastoma

Zong-Yu YuTri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Search for other papers by Zong-Yu Yu in
Current site
Google Scholar
PubMed
Close
,
Ming-Hsuan ChungTri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Search for other papers by Ming-Hsuan Chung in
Current site
Google Scholar
PubMed
Close
 MD
,
Peng-Wei WangTri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Search for other papers by Peng-Wei Wang in
Current site
Google Scholar
PubMed
Close
 MD
,
Yi-Chieh WuTri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Search for other papers by Yi-Chieh Wu in
Current site
Google Scholar
PubMed
Close
 MD
,
Hsiang-Chih LiaoTri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Search for other papers by Hsiang-Chih Liao in
Current site
Google Scholar
PubMed
Close
 MD
, and
Dueng-Yuan HuengTri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Search for other papers by Dueng-Yuan Hueng in
Current site
Google Scholar
PubMed
Close
 MD, PhD
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
USD  $45.00
USD  $515.00
USD  $612.00
Print or Print + Online Sign in
  • Collapse
  • Expand

Illustration from Di Somma et al. (pp 1187–1190). Published with permission from Glia Media | Artist: Martha Headworth, MS.

  • 1

    Mijderwijk HJ, Nieboer D, Incekara F, et al. Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma. J Neurosurg. Published online January 14, 2022. doi: 10.3171/2021.10.JNS211261

    • Search Google Scholar
    • Export Citation
  • 2

    Karsy M, Neil JA, Guan J, Mahan MA, Colman H, Jensen RL. A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus. 2015;38(3):E4.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    Ma HI, Chiou SH, Hueng DY, et al. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Neurosurg. 2011;114(3):651662.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4

    Tamura K, Aoyagi M, Ando N, et al. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy. J Neurosurg. 2013;119(5):11451155.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5

    Rathore S, Akbari H, Rozycki M, et al. Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1. Sci Rep. 2018;8(1):5087.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 1

    Mijderwijk HJ, Steyerberg EW, Steiger HJ, Fischer I, Kamp MA. Fundamentals of clinical prediction modeling for the neurosurgeon. Neurosurgery. 2019;85(3):302311.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2

    Siegal T. Clinical relevance of prognostic and predictive molecular markers in gliomas. In: Scramm J, ed.Advances and Technical Standards in Neurosurgery. Vol 43. Springer;2016:91108.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3

    Weller M, Bent M van den, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170186.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4

    Mohile NA, Messersmith H, Gatson NT, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol. 2022;40(4):403426.

  • 5

    Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):12311251.

  • 6

    Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009;27(34):57435750.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469474.

  • 8

    Nieboer D, Vergouwe Y, Ankerst DP, Roobol MJ, Steyerberg EW. Improving prediction models with new markers: a comparison of updating strategies. BMC Med Res Methodol. 2016;16(1):128.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9

    Mijderwijk HJ, van Beek S, Nieboer D. Updating clinical prediction models: an illustrative case study. Acta Neurochir Suppl. 2022;134(109):113.

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 539 539 44
Full Text Views 55 55 11
PDF Downloads 75 75 8
EPUB Downloads 0 0 0